FDA Clearance Tracker · K060875
ABBOTT AXSYM TROPONIN-I ADV
Last checked: Nov 21, 2026Latest source record: Jun 14, 2006 (this decision)Source: openFDAMethods & limitations
Decided
Jun 14, 2006
Substantially Equivalent
Time to decision
76 days
Received Mar 30, 2006. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K060875
- Device name
- ABBOTT AXSYM TROPONIN-I ADV
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Mar 30, 2006
- Decided
- Jun 14, 2006
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Immunoassay Method, Troponin Subunit (MMI)
- Device class
- Class II
- Regulation
- 21 CFR 862.1215
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MMI. The earliest in FDA's data is K924392, decided Apr 26, 1994.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K060875
- The applicant filed a summary instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.